This is a preview of subscription content, log in via an institution to check access.
Notes
dipeptidly peptidase IV inhibitors and glucagon-like peptide analogues, respectively
sodium glucose transporter-2 inhibitors
Reference
Decision Resources. In Brazil, Mexico and Argentina, High Out-of-Pocket Costs For DPP-IV Inhibitors and GLP-1 Analogues Greatly Limit Prescribing of These Drugs in the Public Setting for the Treatment of Type 2 Diabetes. Media Release : 2 Jul 2013. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
Limited coverage for newer T2DM treatments in Latin America. PharmacoEcon Outcomes News 682, 11 (2013). https://doi.org/10.1007/s40274-013-0557-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0557-5